Lexicon Pharmaceuticals, Inc. (LXRX) stock
LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3087% above fair value
$1.78+0.03 (+1.71%)
Close on Nov 17, 2026Market cap $792.02MP/E –Yield –
Lexicon Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Lexicon Pharmaceuticals's cash was $190.61M at Jun 30, 2026. For fiscal 2025 it was $96.23M, down 59.6% from the year before. Over ten years it grew -15.5% a year on average. The highest annual figure on record is $521.35M in fiscal 2015.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $96.23M | -59.6% |
| FY2024 | Dec 31, 2024 | $237.96M | +40.0% |
| FY2023 | Dec 31, 2023 | $170.03M | +22.9% |
| FY2022 | Dec 31, 2022 | $138.36M | +59.5% |
| FY2021 | Dec 31, 2021 | $86.74M | -43.0% |
| FY2020 | Dec 31, 2020 | $152.28M | -43.9% |
| FY2019 | Dec 31, 2019 | $271.66M | +69.7% |
| FY2018 | Dec 31, 2018 | $160.05M | -48.5% |
| FY2017 | Dec 31, 2017 | $310.79M | -10.3% |
| FY2016 | Dec 31, 2016 | $346.50M | -33.5% |
| FY2015 | Dec 31, 2015 | $521.35M | +53.6% |
| FY2014 | Dec 31, 2014 | $339.34M | +162.8% |
| FY2013 | Dec 31, 2013 | $129.13M | -42.1% |
| FY2012 | Dec 31, 2012 | $223.21M | -20.8% |
| FY2011 | Dec 31, 2011 | $281.69M | +33.4% |
| FY2010 | Dec 31, 2010 | $211.11M | +109.9% |
| FY2009 | Dec 31, 2009 | $100.55M | +17.1% |
| FY2008 | Dec 31, 2008 | $85.87M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $190.61M | +13.5% |
| Q1 FY2026 | Mar 31, 2026 | $170.66M | -12.4% |
| Q4 FY2025 | Dec 31, 2025 | $96.23M | -59.6% |
| Q3 FY2025 | Sep 30, 2025 | $115.95M | -55.1% |
| Q2 FY2025 | Jun 30, 2025 | $168.01M | -45.8% |
| Q1 FY2025 | Mar 31, 2025 | $194.84M | -45.2% |
| Q4 FY2024 | Dec 31, 2024 | $237.96M | +40.0% |
| Q3 FY2024 | Sep 30, 2024 | $258.37M | +18.3% |
| Q2 FY2024 | Jun 30, 2024 | $309.96M | +20.7% |
| Q1 FY2024 | Mar 31, 2024 | $355.60M | +235.7% |
| Q4 FY2023 | Dec 31, 2023 | $170.03M | +22.9% |
| Q3 FY2023 | Sep 30, 2023 | $218.43M | +60.4% |
| Q2 FY2023 | Jun 30, 2023 | $256.74M | +314.3% |
| Q1 FY2023 | Mar 31, 2023 | $105.94M | +22.5% |
| Q4 FY2022 | Dec 31, 2022 | $138.36M | +59.5% |
| Q3 FY2022 | Sep 30, 2022 | $136.20M | +12.6% |
| Q2 FY2022 | Jun 30, 2022 | $61.97M | -47.7% |
| Q1 FY2022 | Mar 31, 2022 | $86.50M | -38.8% |
| Q4 FY2021 | Dec 31, 2021 | $86.74M | -43.0% |
| Q3 FY2021 | Sep 30, 2021 | $120.92M | +8.5% |
| Q2 FY2021 | Jun 30, 2021 | $118.50M | -41.3% |
| Q1 FY2021 | Mar 31, 2021 | $141.36M | -43.3% |
| Q4 FY2020 | Dec 31, 2020 | $152.28M | -43.9% |
| Q3 FY2020 | Sep 30, 2020 | $111.45M | -62.4% |
| Q2 FY2020 | Jun 30, 2020 | $201.87M | +90.5% |
| Q1 FY2020 | Mar 31, 2020 | $249.14M | +87.1% |
| Q4 FY2019 | Dec 31, 2019 | $271.66M | +69.7% |
| Q3 FY2019 | Sep 30, 2019 | $296.30M | +58.2% |
| Q2 FY2019 | Jun 30, 2019 | $105.98M | -56.5% |
| Q1 FY2019 | Mar 31, 2019 | $133.15M | -49.2% |
| Q4 FY2018 | Dec 31, 2018 | $160.05M | -48.5% |
| Q3 FY2018 | Sep 30, 2018 | $187.30M | -4.8% |
| Q2 FY2018 | Jun 30, 2018 | $243.55M | +5.3% |
| Q1 FY2018 | Mar 31, 2018 | $262.27M | +1.0% |
| Q4 FY2017 | Dec 31, 2017 | $310.79M | -10.3% |
| Q3 FY2017 | Sep 30, 2017 | $196.82M | -50.2% |
| Q2 FY2017 | Jun 30, 2017 | $231.19M | – |
| Q1 FY2017 | Mar 31, 2017 | $259.74M | – |
| Q4 FY2016 | Dec 31, 2016 | $346.50M | – |
| Q3 FY2016 | Sep 30, 2016 | $395.56M | – |
See a number that looks wrong?